Incyte Reports 2018 Third Quarter and Nine Month Financial Results and Provides Updates on Key Clinical Programs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Incyte Reports 2018 Third Quarter and Nine Month Financial Results and Provides Updates on Key Clinical Programs

Incyte (INCY) PT Lowered to $78 at RBC Capital

October 31, 2018 7:47 AM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Incyte (NASDAQ: INCY) to $78.00 (from $79.00) while maintaining a Outperform rating.

... More

Incyte (INCY) Misses Q3 EPS by 2c, Revenues Miss; Lifts FY18 Revenue Mid-Point, Remains Below Consensus

October 30, 2018 7:08 AM EDT

Incyte (NASDAQ: INCY) reported Q3 EPS of $0.38, $0.02 worse than the analyst estimate of $0.40. Revenue for the quarter came in at $430 million versus the consensus estimate of $450.38 million.

Total product-related revenues of $430 million for the three months and $1.2 billion for the nine months ended September 30, 2018; Jakafi® (ruxolitinib) revenues of $348 million in 3Q 2018 and $1.0 billion YTD... More